Arrowhead Pharmaceuticals has reported top line results from the Phase III SHASTA-3 and SHASTA-4 trials investigating plozasiran in sHTG patients.

The post Arrowhead announces top line data from Phase III trials of plozasiran appeared first on Clinical Trials Arena.